Scarica l'app Stockscreener
22.47
1.75%
-0.40
Dopo l'orario di chiusura:
22.47
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Wellington Management Group LLP Purchases 36,267 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Lord Abbett & CO. LLC Takes Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
When the Price of (ELVN) Talks, People Listen - Stock Traders Daily
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by BTIG Research - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Clear Street sets Enliven Therapeutics stock to buy with $36 target - Investing.com Canada
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 6.8%Should You Buy? - MarketBeat
Janus Henderson Group PLC Purchases 313,019 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by RA Capital Management L.P. - MarketBeat
Patient Square Capital LP Takes $2.31 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Walleye Capital LLC Takes $2.54 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Fmr LLC Boosts Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics CFO Benjamin Hohl sells $130,688 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics CFO Benjamin Hohl sells $130,688 in stock - Investing.com
Comparing Enliven Therapeutics (NASDAQ:ELVN) & Terns Pharmaceuticals (NASDAQ:TERN) - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 3%What's Next? - MarketBeat
Ally Bridge Group NY LLC Takes $6 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Acuta Capital Partners LLC Sells 101,330 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 - Marketscreener.com
(ELVN) Investment Analysis - Stock Traders Daily
Enliven Therapeutics to Present at the Jefferies London Healthca - GuruFocus.com
Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Increases By 6.1% - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by First Turn Management LLC - MarketBeat
Robert W. Baird Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - Defense World
Enliven Therapeutics has cash runway into late 2026 - BizWest
Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
RA Capital Management, L.P. Reduces Stake in Enliven Therapeutics Inc. - GuruFocus.com
COMMODORE CAPITAL LP Expands Stake in Enliven Therapeutics Inc - GuruFocus.com
Citadel Advisors LLC Adjusts Stake in Enliven Therapeutics Inc - GuruFocus.com
Enliven Therapeutics Reports Q3 Results and Clinical Progress - TipRanks
Polar Capital Holdings Plc's Strategic Acquisition in Enliven Th - GuruFocus.com
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PR Newswire
(ELVN) Investment Analysis and Advice - Stock Traders Daily
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference - StockTitan
How to Take Advantage of moves in (ELVN) - Stock Traders Daily
Jones Trading Initiates Coverage of Enliven Therapeutics (ELVN) with Buy Recommendation - MSN
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 - Investing.com
Enliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02 - MSN
Enliven Therapeutics chief medical officer sells $24,482 in stock - Investing.com India
Enliven Therapeutics CFO sells $24,422 in stock - Investing.com
Enliven Therapeutics chief medical officer sells $24,482 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics COO Anish Patel sells $21,482 in stock - Investing.com
Enliven Therapeutics COO Anish Patel sells $21,482 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CFO sells $24,422 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics' chief scientific officer sells $25,412 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CEO Kintz sells $27,722 in stock - Investing.com
Enliven Therapeutics' chief scientific officer sells $25,412 in stock - Investing.com India
Enliven Therapeutics director Heyman sells $47,104 in stock By Investing.com - Investing.com Australia
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):